Dexcom has received Food and Drug Administration clearance for the first over-the-counter glucose sensor for children. The ...
Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...
New study results could lead to better insurance coverage of the devices for people who don’t take insulin, a researcher said ...
The U.S. Food and Drug Administration (FDA) on Friday cleared Dexcom Inc.‘s DXCM Stelo Glucose Biosensor System for ...
This popular CGM can now be marketed for children 2 years of age and older who do not use insulin.
Compare Apple Watch CGM apps for blood sugar readings, including Dexcom G7, FreeStyle Libre, and Eversense watch support.
DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six ...
Zacks Investment Research on MSN
Dexcom reports positive CONNECT data for non-insulin diabetes
DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...
Dexcom shares plunged on disappointing revenue and weak guidance. The stock was down 13% for the year as of Thursday's close. Dexcom makes continuous glucose monitors for patients with diabetes. In ...
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results